Skip to main content

Published locations for FDA to review PDE4-inhibitor roflumilast for psoriasis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA to review PDE4-inhibitor roflumilast for psoriasis

User login

  • Reset your password
  • /content/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /clinicianreviews/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /edermatologynews/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /familypracticenews/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /internalmedicinenews/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /pediatricnews/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /pediatrics/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /internalmedicine/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /dermatology/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis
  • /familymedicine/article/250322/psoriasis/fda-review-pde4-inhibitor-roflumilast-psoriasis